COVID-19 Booster Readiness Survey

The purpose of this administrative survey is to inform health system logistics by assessing the attitudes towards towards the bivalent COVID-19 boosters held by healthcare workers (HCWs) at a large, rural health system. It will also test, prospectively, the effect on interest in the bivalent COVID-19 booster of different framing approaches in a survey question sent to employees of a large, rural health system.

Study Overview

• Status: Completed
• Conditions: Vaccination Refusal
• Intervention / Treatment: Behavioral: Salience of Omicron variant; Behavioral: Self-protection message; Behavioral: Other-protection message

Detailed Description

The Food and Drug Administration has authorized two bivalent COVID-19 boosters with the expectation that the Centers for Disease Control will soon recommend them. The researchers plan to survey the HCWs at a large, rural health system on their attitudes on the bivalent booster.

This survey will gather data on HCWs' interest in a bivalent booster, reasons for hesitancy, risk perception about COVID-19 infection and its complications, and prior COVID-19 infection and vaccination.

Respondents will also be randomly assigned to see different versions of the question asking if they are interested in a bivalent booster with different framing approaches, such as protection of the self or protection of patients (for patient-facing employees). Information on prior vaccination and perceptions of risk will also be gathered and used as covariates in the analysis.

• Study Type: Interventional
• Enrollment (Actual): 12036
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Pennsylvania
    • Danville, Pennsylvania, United States, 17822
      • Geisinger Clinic

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Employee at the health system

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
No Intervention: Standard question; Question with no additional text or framing
Experimental: Question with salient Omicron message; Question indicates that the bivalent booster can protect the respondent from the Omicron variant	Behavioral: Salience of Omicron variant; The message mentions the Omicron variant, which can be a fear appeal or make salient the reason for the new booster; Behavioral: Self-protection message; The message makes a reference to protecting one's self
Experimental: Question with patient protection message; Question indicates that the bivalent booster can protect patients (only presented to patient-facing employees)	Behavioral: Other-protection message; The message makes a reference to protecting others (patients)
Experimental: Question with salient Omicron and patient protection message; Question indicates that the bivalent booster can protect patients from the Omicron variant (only presented to patient-facing employees)	Behavioral: Salience of Omicron variant; The message mentions the Omicron variant, which can be a fear appeal or make salient the reason for the new booster

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Count of employees who indicate interest in the booster	Number of employees who indicate that they plan to get the booster when it is available	14 days

Collaborators and Investigators

• Sponsor: Geisinger Clinic
• Investigators: Principal Investigator: Michelle N Meyer, PhD, Geisinger Clinic

Study record dates

Study Major Dates

• Study Start (Actual): September 1, 2022
• Primary Completion (Actual): September 15, 2022
• Study Completion (Actual): September 15, 2022

Study Registration Dates

• First Submitted: September 1, 2022
• First Submitted That Met QC Criteria: September 1, 2022
• First Posted (Actual): September 6, 2022

Study Record Updates

• Last Update Posted (Actual): September 30, 2022
• Last Update Submitted That Met QC Criteria: September 28, 2022
• Last Verified: September 1, 2022

More Information

Terms related to this study

• Keywords: Vaccination; Communication; Economics, Behavioral; Surveys and Questionnaires
• Other Study ID Numbers: 2022-0726

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Data with no personally identifiable information will be made available to other researchers on the Open Science Framework for transparency. This will include the essential data and code needed to replicate the analysis that yielded reported findings.
• IPD Sharing Time Frame: By the paper's online publication date. Data will remain available for as long as the Open Science Framework hosts it.
• IPD Sharing Access Criteria: The data on the Open Science Framework will be open to anyone requesting that information.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ANALYTIC_CODE

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No